First patient enrolled in jdrf-funded phase ii trial of cpp-1x-t for recent onset type i diabetes, led by indiana university school of medicine

Minneapolis, april 12, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a phase ii double-blind, randomized study to evaluate cpp-1x-t (eflornithine tablets) for recent onset type 1 diabetes. the multi-site clinical trial is led by researchers at indiana university school of medicine and funded by jdrf, the leading global type 1 diabetes research and advocacy organization.
PBLA Ratings Summary
PBLA Quant Ranking